Indivior To Discontinue Sublocade Sales In Australia By End Of 2026

Indivior announced it will discontinue the marketing and sale of Sublocade in Australia after December 2026. Sublocade is a once-monthly injectable treatment for opioid use disorder (OUD) administered by a health care professional.

Indivior confirmed to OPEN MINDS that it made the commercial decision to discontinue the marketing and sale of Sublocade in Australia. The company stated it is committed to maintaining sufficient supply of Sublocade to support continuity of care until the proposed final reimbursement claim date of December 31, 2026, and intends to work with Australian authorities and clinical experts to support an orderly transition that minimizes . . .